Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against Salmonella Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocol

Key Points

• Bivalent vaccination aims to protect against both Salmonella typhi and paratyphi A infections, enhancing public health.
• The trial uses a controlled human infection model to assess the vaccine's effectiveness on induced infections.
• Randomised controlled trial protocol involves multiple centers to ensure diverse participant recruitment and reliability of results.
• The findings may highlight new strategies for preventing paratyphoid fever, potentially beneficial on a global scale.